Drug can delay ovarian cancer relapses: study

A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.

About 70 percent of patients with advanced experience a relapse following surgery and chemotherapy and need to resume . The deadly disease's cure rate is just 20 to 25 percent.

German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median time to disease worsening to 17.9 months compared with 12.3 months for patients given a placebo in a phase III clinical trial.

"Our findings show that we finally have a drug that can maintain control over ovarian achieved through initial treatments," said lead author Andreas du Bois, a professor of gynecologic oncology at Kliniken Essen Mitte in Germany.

"If pazopanib is approved for ovarian cancer, many patients will experience longer disease-free and chemotherapy-free periods. During this time, the patient keeps control over the disease instead of the disease having control over the patient's life."

An estimated 22,240 new cases of ovarian cancer are expected to be detected in the United States in 2013, and 14,030 women are expected to die from the disease this year.

There are currently no drugs approved in the United States as maintenance therapies for patients who've undergone treatment for advanced ovarian cancer, although Europe has approved Genentech's bevacizumab (Avastin) for that use.

Pazopanib is an that blocks several targets involved in the growth of tumors and their blood vessels.

The study was presented at the annual meeting of the American Society of Clinical Oncology (ASCO.)

"Relapses remain all too common for women with advanced ovarian cancer," said Carol Aghajanian, an ASCO spokeswoman and expert.

"This large trial shows us that targeting multiple molecular cancer drivers can have a substantial impact on this cancer's ability to grow, giving our patients significantly longer time before relapse."

add to favorites email to friend print save as pdf

Related Stories

Drug cocktail boosts ovarian cancer survival time

Jun 02, 2012

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

SOG: Intraperitoneal chemo ups ovarian cancer survival

Mar 12, 2013

(HealthDay)—Intraperitoneal (IP) chemotherapy is associated with improved survival in advanced ovarian cancer compared with standard intravenous (IV) therapy, according to a study presented at the Society ...

Targeted toxin active in platinum-resistant ovarian cancers

Apr 06, 2013

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual ...

Chemoresponse assay helps boost ovarian cancer survival

Apr 25, 2013

This spring, a team of researchers has released results from an eight-year study that shows improved survival rates for women diagnosed with ovarian cancer who undergo cancer tumor testing to determine the best treatment.

Recommended for you

ACG: Recent increase in incidence of young-onset CRC

4 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments